Evidence map›Paper›PMID 31138900›Full record

ArticleCancer gene therapy2020

HJURP knockdown disrupts clonogenic capacity and increases radiation-induced cell death of glioblastoma cells.

Rodolfo B Serafim, Cibele Cardoso, Luis F M Di Cristofaro, Christiane Pienna Soares, Wilson Araújo Silva, Enilza M Espreafico, Maria L Paçó-Larson, Brendan D Price, Valeria Valente

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Rodolfo B SerafimDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Cibele CardosoDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Luis F M Di CristofaroDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Christiane Pienna SoaresSão Paulo State University (UNESP), School of Pharmaceutical Sciences,, Rodovia Araraquara - Jaú, Km 01 - s/n, Campos Ville, Araraquara, SP, 14800-903, Brazil.
Wilson Araújo SilvaDepartment of Genetics, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Enilza M EspreaficoDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Maria L Paçó-LarsonDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil.
Brendan D PriceDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Valeria ValenteDepartment of Cellular and Molecular Biology, Ribeirão Preto Medical School, University of São Paulo (USP), Avenida Bandeirantes, 3900, Ribeirão Preto, 14049-900, Brazil. valenteval@gmail.com.
Universidade de São Paulo · BRCentro Universitário de Araraquara · BRDana-Farber Cancer Institute · USFundação de Amparo à Pesquisa do Estado de São Paulo · BR

Funding

Identifying the roles of DNA rewinding enzymes on maintaining genome stabilityR01GM114304 · NIGMS · DANA-FARBER CANCER INST · PI PRICE, BRENDAN D · 2015 to 2019
$1.7M
6 · The paper itself

Abstract

The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centromeric Protein A (CENP-A)-at the centromeres in a cell cycle-regulated manner, being required for proper chromosome segregation. Here we investigated HJURP association with survival and radioresistance of different GBM cell lines. HJURP knockdown compromised the clonogenic capacity and severely impaired survival of five distinct GBM cells, while nontumor astrocytes were not affected. U251MG cells showed a robust cell cycle arrest in G2/M phases followed by a drastic increment in cell death after HJURP silencing, while U138MG and U343MG cell lines presented augmented senescence with a comparable increase in cell death. Importantly, we verified that the impact on cell cycle dynamics and clonogenic survival were associated with loss CENP-A at the centromeres. Moreover, radiation resistance was also impacted by HJURP modulation in several GBM cell lines. U87MG, T98G, U138MG, and U343MG cells were all sensitized to ionizing radiation after HJURP reduction. These data reinforce the requirement of HJURP for proliferative capacity and radioresistance of tumor cells, underlining its potential as a promising therapeutic target for GBM.

Indexed as

Brain NeoplasmsCell Cycle CheckpointsCell Line, TumorCell ProliferationCell SurvivalCentromereCentromere Protein ADNA-Binding ProteinsGene Knockdown TechniquesGlioblastomaHumansNeoplastic Stem CellsRadiation ToleranceTumor Stem Cell AssayCENPA protein, humanCentromere Protein ADNA-Binding ProteinsHJURP protein, human

Identifiers

PMID31138900
OpenAlexW2947942034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.